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Abstract Previous studies performed in selected popula-
tions show a poor utilization of triptans for migraine. The
objectives of our study were to establish patterns of triptans
utilization in a large sample, covering 1/10 of Italian popula-
tion (5.57 millions), and to perform a review of published
studies on this topic. We investigated drug prescription data-
base collected during 2006 from 33 health authorities
distributed in 8 different regions. About 0.6% of the subjects
received at least one prescription of triptans in 1 year: 77.7%
were females and 22.3% males. Age distribution shows that
9.5% of patients were aged above 65, and received prescrip-
tions for 8.2% of packages. The review of the literature
suggests that these percentages of utilization are common to
several countries, and shows that occasional triptan users who
received only one prescription in 1 year are a large percentage
(40–60%); moreover, a minor population of triptan users uti-
lize a large amount of total triptans. Finally triptans are
frequently prescribed in people aged above 65 years, a popu-
lation in which triptans are contraindicated or not
recommended. Our study and the analyzed ones indicate
suboptimal treatment of migraine patients with triptans and
also an incorrect use in some patients (triptan abusers, elderly).
Keywords Triptans  Triptan abusers  Usage patterns 
Prescription data  Literature review
Introduction
Since the commercialization of the new antimigraine drug
sumatriptan about 20 years ago, scientific societies,
pharmaceutical companies and headache specialists, have
tried to highlight the migraine pathology in the population,
arguing that it was underestimated. In the following years
many other drugs, in the pharmacological class of triptans,
became available.
The average percentage of migraine in the world is
regarded as around 9% of the overall population [1].
However, until today, migraine remains under-diagnosed
and under-treated in at least 50% of patients, and less than
50% of migraine patients had consulted a physician [1, 2].
The efficacy of triptans has been shown in several ran-
domized, double-blind, placebo-controlled trials [3].
However these studies were carried out in selected popu-
lations and under controlled conditions. Utilization patterns
of specific anti-migraine drugs in community patients and
the experiences of patients with these drugs in real life
setting have been studied less extensively. Recently we
have performed a study evaluating triptans utilization in a
health authority in Tuscany covering about 225,000 resi-
dents [4, 5]. We have extended this study to establish the
patterns of use of triptans in a large sample of Italian
population [6] and review other studies on this topic.
Materials and methods
Study on the Italian population
In the reimbursement system of the Italian National Health
Service, all prescribed drugs included within the essential
level of assistance (LEA) are recorded by regional health
authorities in association with the demographic character-
istics of patients. Therefore, medication records of
individual patients are quite complete in drugs prescription
databases. This allows for accurate investigations in drug
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utilization in our setting. The patterns of triptans pre-
scription in the 33 health authorities distributed in 8 Italian
regions were investigated. The population studied was
5.57 millions inhabitants, that represents 9.5% of the Ital-
ian population. We analysed prescription database using
the ATC classification (Anatomical Therapeutic Chemical
classification) NO2CC: triptans, dispensed during 1 year
(2006).
In Italy each prescription of triptans could contain one
or two packages. In 2006, all triptans (except naratriptan)
were available as oral tablets in Italy, for rizatriptan and
zolmitriptan as soluble oral tablets, sumatriptan as subcu-
taneous injections, nasal spray and rectal suppositories.
The doses contained in each package of triptans available
in Italy are reported in Table 1.
Literature review
Studies were identified through a Medline search on
Internet (Pubmed Medline, 2000 version; address
http://www4.ncbi.nlm.nih.gov/PubMed/). This search cov-
ered the period from 1991 to June 2007.
Results
Study on the Italian population
Demographic characteristics of the population studied are
reported in Table 2.
On a total of 5,549,731 resident population, the subjects
that received triptans were 32,584 (0.6% of the population),
22.3% males and 77.7% females. Males and females aged
15–44 represented 51.4% of total users, while those aged
45–65 were 38.7%. The patients aged over 65 years were
9.5%. The total number of triptan packages prescribed was
312,337 (Table 3). We found the higher dosage (DDD/
1,000 inhabitants/day, DDD = defined daily dose) in the
45–64 years group. The DDD/1,000 inhabitants/day was:
0.004 (0–14 years), 0.813 (15–44 years), 1.324 (45–
64 years), 0.446 (65–74 years), 0.216 (75–84 years), 0.122
([85 years).
The distribution of triptan packages prescribed was: ri-
zatriptan 26%, sumatriptan 20.1%, almotriptan 17.3%,
zolmitriptan 13.9%, eletriptan 12.6%, frovatriptan 10%.
Literature review
Prevalence of triptan users
A prescription register survey in Denmark revealed that
nearly 1% of the population recurred to sumatriptan in 1-
year period [7]. Other studies describing the percentage of
triptan users, in periods when more triptans are available,
are reported in Table 4 [5, 6, 8–15]. The prevalence of
triptan users in a year period was 0.55–1.4%. Some of these
studies [8, 12, 13] were performed on new users of triptans
who were defined as patients who had not received any
triptan in the period preceding the study. The new users
account for 25–63% of total users, depending on the period
Table 1 Dosage units contained in triptans packages available in
Italy in 2005–2006
Triptans Packages Dosage units
Sumatriptan Tablet 50–100 mg 4
Sumatriptan Suppository 25 mg 2
Sumatriptan Nasal spray 10–20 mg 2
Sumatriptan Injection 6 mg 2
Zolmitriptan Tablet 2.5 mg 3
Zolmitriptan Soluble tablet 2.5 mg 2
Rizatriptan Tablet 5–10 mg 3
Rizatriptan Soluble tablet 10 mg 3
Eletriptan Tablet 20–40 mg 3
Almotriptan Tablet 12.5 mg 3
Flovatriptan Tablet 2.5 mg 2
Flovatriptan Tablet 2.5 mg 6
Table 2 Demographic characteristics of the population studied
Age Males Females Total
0–14 370,058 348,222 718,280
15–44 1,141,606 1,108,199 2,249,805
45–64 697,013 722,045 1,419,058
65–74 280,037 329,408 609,445
75–84 169,295 258,847 428,142
[85 38,358 86,643 125,001
Total 2,696,367 2,853,364 5,549,731
Table 3 Pattern of triptans utilization in a sample of 5,549,731
Italian residents
Age Users (%) Packages (%) DDD/1,000
inhabitants/day
0–14 0.2 0.08 0.004
15–44 51.4 46.1 0.813
45–64 38.7 45.5 1.324
65–74 6.2 5.9 0.446
75–84 2.7 1.9 0.216
[85 0.6 0.3 0.122
Total (no.) 32,584 312,337
DDD defined daily dose
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of study and the period considered without assumption
preceding the study (Table 5).
The prevalence of triptans utilization in migraine
patients in different countries was reported to be 3–19%
(average 10%) [1], while other population studies show a
similar prevalence: 7.5% [16], 8% [17], 9.8% [18].
Therefore the percentage of triptan utilization in the pop-
ulation has a good relation to the pathology, showing that
less than 10% of patients use a triptan.
Migraine patient referred to headache clinics, increase
the rate of triptans assumption after consultation [19, 20].
Frequency of triptan use
About 40–60% of triptans users received only one pre-
scription in 1 year (Fig. 1). Single users of sumatriptan
were also reported to be over 40% [21, 22].
Lohman et al. [9] report that 12.5% of triptan users
utilized more than one drug product and received 25% of
the total number of dosage units. Ifergane et al. [12] report
that, among patients who filled more than one prescription,
14.3% tried a second triptan; in this group 52.1% pur-
chased only one prescription of the new triptan. Tepper
et al. [23] showed that 91% of the patients remained on the
same triptan during the study period. In conclusion 10–
15% of triptans users change the type of triptan during the
period of 1 year.
On the other hand, a minority of triptan users utilize a
large percentage of annual triptan prescriptions (Table 6).
A population study in Denmark too showed that a minority
of sumatriptan users (5%) were taking this medication on a
daily basis accounting for 38% of all sumatriptan use [7].
A comparison of intensity of triptan utilization in dif-
ferent countries cannot be performed considering the
number of triptan packages, because triptan packages may
contain different number of doses depending on marketing
policies. Then a comparison of studies must be performed
considering doses or DDD (Table 7).
Initial studies on triptan abuse concerned sumatriptan [7,
24]. The critical intake frequency for patients with triptan
Table 4 Prevalence of triptans users in population studies
Study Country/Year Population Users Period Percentage Females (%)
Etemadc [8] USA 1998–2000 [2,000,000 8,488 1 year \0.42 83.6
Lohmana [9] Netherlands 2001–2002 168,000 2,343 1 year 1.4 78
Perearnau [10] France 2003–2004 1,793,000 20,686 1 year 1.15 78.5
Pavone [5] Italy 2005 224,065 1,238 1 year 0.55 77.9
Dekker [11] Netherlands 2005 6,700,000 85,172 1 year 1.27 NR
Panconesi [6] Italy 2006 5,549,731 32,584 1 year 0.6 77.7
Iferganec [12] Israel 2003–2004 500,000 1,498 1 year 0.3 77.1
Lugardonc [13] France 2002 1,550,000 13,860 6 months 1.0 80.6
Sondergaard [14] Denmark 2000 472,000 2,463 3 months 0.52 82.7
Hoffmanb [15] USA 1999 600,000 4,718 3 months 0.78 NR
NR not reported
a enclosed also ergotamine, benclosed also dihydroergotamine nasal spray, cnew users
Table 5 Percentage of new users of triptans
Study Antecedent period Study period Population Total users New users New users (%)
Lugardona (France 2002) [13] 6 months 6 months 1,550,000 13,860 8,625 63
Sondergaard (Denmark 2000) [14] 9 months 3 months 472,000 2,463 617 25
Etemad (USA 1988) [8] 6 months 1 year 2,000,000 8,488 5,383 63













Lugardon S.*  [13]        
(2002-France)
Ifergane G.* [12]          
(2003-Israel)
Etemad LR * [8]      
(1998-USA)
Lohman JJHM [9]        
(2001-Netherlands)
 Pavone E. [5]      
(2005-Italy)
Fig. 1 Percentage of patients receiving only one triptan prescription
during 1 year. * New users
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overuse headache, is reported to be 18 single doses of
triptans per month [25]. Then, considering 216 tablets/year
as critical doses for triptan overuse, the percentage of
patients overusing triptans are 0.9–3.3% of all triptans
users (Table 8). However, ten single dosages per month
(120 doses/year) may be sufficient to cause triptans over-
use headache and therefore should be considered a critical
threshold [25, 26]. Therefore, in various studies 3.2–11.9 of
patients are possible triptan abusers (Table 8). We cannot
classify these patients as suffering of triptan-overuse
headache, that is with code 8.2.2 of the International
Headache Society (IHS) classification [26], because we do
not know their clinical characteristics (headache present on
[15 day/month, with frequency increased during triptan
overuse and impaired within 2 months after triptan
discontinuation) and the number of days of triptans intake.
However, these patients are probably at risk for developing
triptans-overuse headache or rather they already developed
this chronic headache.
A consistent percentage of triptans is prescribed for
people over the age of 65. In the Italian population this
percentage is 7.6–9.5% [5, 6], higher than that reported
(3.2–3.5%) in the France population [10, 27]. A previous
study shows that sumatriptan users over 65 years were 3%
[28]. This is a population at major risk of hypertension and
cardiovascular diseases, and it is also a population in which
clinical trials have been not performed and so triptans are
not recommended.
Discussion
The main conclusions coming from these studies are:
• A very low percentage (about 10%) of migraine
patients utilized triptans.
• When utilized, triptans were prescribed only once in a
year in a large percentage (40–60%) of patients.
• A minority of patients (5–10%) utilize a large amount
(40–45%) of triptans, and some of these are classified
as triptans abusers.
• A considerable percentage of triptans are prescribed in
people aged over 65.
• The low percentage of triptans users can be due to the
low rate of diagnosis of migraine and the high
utilization of over-the-counter drugs (OTC). Less than
50% of people suffering from migraine are not
recognized by their general practitioner as having
migraine and less than 30% of these have adequate
management of migraine [29]. Possible causes of
underdiagnosis and management by general practi-
tioner are: poor time to spend with the patient,
complexity of diagnostic criteria of IHS [26], variabil-
ity of the clinical manifestations in migraine patients
[30, 31], high utilization of OTC drugs [1], and high
cost of triptans.
The high percentage of single prescriptions of triptans
could indicate that many migraine patients had low
frequency of attacks; in fact it was reported that only
20% patients had more than 14 migraine days per year
[32]. Other studies reported an higher frequency: 75% of
migraine patients have 0–3 attacks/months and 25% more
than one attack/week [2, 17]. Another interpretation of the
low percentage and frequency of triptans use is that many
migraine patients cannot completely control migraine by
triptans therapy because of lack of efficacy and/or side
effects. Rahimtoola et al. [28] found that the main reasons
for discontinuing treatment after only one prescription, was
Table 6 Few patients (%) of total triptan users consume a large






7.9 43.6 of intakes
Dekker (Netherlands 2005)
[11]
10.4 46 of cost
Pavone (Italy 2005) [5] 5.7 40 of packages or 44 of
DDDs
DDD defined daily dose
Table 7 Month frequency of triptan assumption
Pavone (2005 Italy) [5] 1.8 DDDs (mean)
Perearnau (2003 France) [10] 2.1 Doses (mean)
Sondergaard (2000 Denmark) [14] 2.7–3.3 Doses (median)
Lohman (2001 Netherlands) [9] 2.9 Doses (mean)
Tepper (2002 USA) [23] 4.2 #–4.6 $ Doses (mean)
DDD defined daily dose
Table 8 Percentage of probable triptans abusers among triptan users
Study Criteria %
Sondergaard (Denmark 2000) [14] [15 DDD/m 4.7
Lugardon (France 2002) [13] 15–29 DDD/m 10.0
[29 DDD/m 1.9
Lohman (Netherlands 2001) [9] [120 DDD/y 5.0
[216 DDD/y 1.9
Dekker (Netherlands 2005) [11] [120 DDD/y 10.4
[216 DDD/y 3.3
Pavone (Italy 2005) [5] [120 DDD/y 3.2
[216 DDD/y 0.9
Perearnau (France 2003) [10] [144 DDD/y 1.9
DDD defined daily dose, m month, y year
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inefficacy and/or the occurrence of side effects. Maybe
some patients tested a triptan but thereafter they do not
require it again. This assumption was supported by the fact
that although new triptan users are a large proportion of
total users, the percentage of triptans users during the years
has remained low. There are reports showing that an
important subset of triptan users is dissatisfied with their
usual care and about 80% would be willing to try another
acute medication [33].
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